Want to see RYTM full AI Analyst Report?
RYTM Stock Chart & Stats
$88.69
-$0.41(-0.68%)
At close: 4:00 PM EST
$88.69
-$0.41(-0.68%)
Day’s Range― - ―
52-Week Range$60.80 - $122.20
Previous CloseN/A
Volume91.33K
Average Volume (3M)753.96K
Market Cap
$7.83B
Enterprise Value$6.74B
Total Cash (Recent Filing)$340.63M
Total Debt (Recent Filing)$227.02M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 04, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding68,593,575
10 Day Avg. Volume980,194
30 Day Avg. Volume753,959
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)50.02
Price to Sales (P/S)36.66
P/FCF Ratio-59.64
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue31.03
Enterprise Value/Gross Profit34.70
Enterprise Value/Ebitda-37.28
Forecast
1Y Price Target
$137.75Price Target Upside55.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.15
Revenue Forecast (FY)$298.08M
Bulls Say, Bears Say
Bulls Say
Revenue Scale & Unit EconomicsRevenue grew materially from 2022 to TTM while gross margins remained very high, demonstrating durable unit economics. High gross margin across periods implies manufacturing and pricing leverage that can support reinvestment and margin expansion as commercialization scales sustainably.
Multi-Region Regulatory WinsSequential regulatory approvals and filings broaden the addressable market structurally. Multiple jurisdiction approvals plus planned EU/Japan launches diversify revenue sources, reduce single-market dependence, and materially increase long-term commercial opportunity for IMCIVREE across rare obesity indications.
Cash Runway To ExecuteA cash balance of roughly $341M and an asserted ≥24‑month runway provides the company funding to complete near‑term launches, planned clinical work, and CMC activities without immediate financing. This reduces near‑term dilution risk and supports strategic execution over the next two years.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow (TTM) reflects ongoing cash burn that historically ranges near -$114M to -$173M annually. Without sustained margin expansion or material revenue growth beyond current trends, the company will likely need external capital, raising dilution and financing risk.
Rising LeverageDebt increased sharply and equity has fallen, producing elevated leverage. Higher debt-to-equity and shrinking shareholder equity reduce financial flexibility, increase refinancing and interest risks, and constrain the company's ability to fund opportunistic investments or weather slower commercial uptake without more costly capital.
Escalating Operating CostsMarked SG&A and R&D increases and a raised operating expense guidance driven by CMC, clinical supply and commercial build create higher fixed cost burden. Profitability now depends on converting launch momentum into sustained, scaleable revenue to offset structurally higher operating expense levels.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $60.80 and its highest was $122.20 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Rhythm Pharmaceuticals Inc’s market cap is $7.83B.
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Aug 04, 2026 which is in 29 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on May 05, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.822 by -$0.008.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -0.81.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 68,593,575 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.822. Following the earnings report the stock price went up 7.864%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in RYTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$137.75 (55.32% Upside)
$137.75 (55.32% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 83%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $428.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 13.0%
Last 30 Days ▲ 13.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
70.60%
12-Months-Change
Fundamentals
Return on Equity
-203.25%
Trailing 12-Months
Asset Growth
14.39%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
RYTM Company Deck
RYTM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and regulatory picture: sequential revenue growth (5%), strong international acceleration (27% QoQ outside U.S.), an encouraging early HO launch (150+ start forms, broad prescriber base), EU marketing authorization and a progressing Japan filing, supported by a solid cash runway (~$341M). Offsetting these positives are meaningful increases in operating expenses (notably SG&A up ~62.7% YoY), ongoing GAAP losses (Q1 EPS -$0.83) and near-term variability and uncertainty tied to payer policy timing, inventory effects and the pace of clinical-to-commercial conversions. Overall, the operational momentum and regulatory wins outweigh the financial and execution risks highlighted for the near term.View all RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
$137.75
▲(55.32% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Ownership Overview
0.85% Insiders
31.38% Mutual Funds
<0.01% Other Institutional Investors
51.56% Public Companies and
Individual Investors